Table 2 Related therapeutic targets: targeting specific RBP
From: Alternative splicing and related RNA binding proteins in human health and disease
Drugs | Target | Therapeutics | Reference |
|---|---|---|---|
VPC-80051 | HNRNPA1 | VPC-80051 directly interacts with HNRNPA1 RBD and reduces the level of AR-V7 mRNA in the 22Rv1 CRPC cell line | |
SPHINX31 | SRPK1 | Inhibits the phosphorylation of SRSF1 and promotes angiogenesis caused by VEGF-A isoforms. | |
Tasisulam, Chloroquinoxaline, sulfonamide, Indisulam | RBM39 | Promotes RBM39 recruitment to the CUL4-DCAF15 E3 ubiquitin ligase, leading to multi-ubiquitination and proteasomal degradation of RBM39 | |
SM09419 | CLK/DYRK | Causes erroneous splicing and inactivation of the apoptosis inhibitor XIAP, downregulating the anti-apoptotic protein BCL2A1 related to venetoclax resistance | |
Auranofin | NONO | Regulates the abnormal ASE of GPX1, inhibiting tumor growth, invasion, and redox balance | |
TG003 | SRSF1 | Inhibits the activity of Clk1/4, leading to the dephosphorylation of SFRS1, thereby inducing the subcellular relocalization of SFRS1 and inhibiting the ASE of SFRS1-dependent pre-mRNA. | |
TG693 | SRSFs | Inhibits the phosphorylation of SRSFs that are substrates of CLK1, and regulates pre-ribonucleic acid splicing in skeletal muscle | |
T025 | SRSFs | Inhibits the phosphorylation of SRSFs that are substrates of CLK2, inducing exon skipping of pre-mRNA AS regulated by SRSF1 | |
PRMT5-IN-31 | PRMT5/HNRNPE1 | Acts as PRMT5 inhibitor/HNRNPE1 upregulator | |
Manumycin-A | Ras signaling, HNRNPH1 | Inhibits the Ras signaling pathway and HNRNPH1 expression to suppress the biogenesis and secretion of CRPC cell exosomes | |
Riluzole | HNRNPA1 | Inhibits IRES-dependent translation, and blocks the binding of HNRNPA1 with cyclin D1 and MYC IRES, thereby significantly reducing the translation efficiency of these transcripts | |
JL014 | HNRNPE1 | Increases the mRNA and protein levels of HNRNP1 in HUVEC | |
Spinraza | HNRNPA1 | Blocks the intron binding site of HNRNPA1, promotes the inclusion of exon 7 of SMN2 and the level of full-length SMN2 mRNA, treating SMA |
